Immunotherapy for advanced or recurrent hepatocellular carcinoma

Table 1 Activity of single immune checkpoint inhibitor from the clinical trials

Drugs (dose)	Other treatment	Targets	Trial identifier	Patient group	n	mOS in mo	ORR, %	DCR, %	mPFS in mo	Phase	Setting
Nivolumab (3 mg/kg every 2 wk)	No	PD-1	NCT01658878	Advanced HCC	214	NR	20.0	64.0	4.00	I-II	1L
Nivolumab (240 mg every 2 wk)	vs Sorafenib	PD-1	NCT02576509	Advanced HCC	371	16.40	15.0	55.0	3.70	III	1L
Pembrolizumab (200 mg every 3 wk)	No	PD-1	NCT02702414	Advanced HCC	104	12.90	17.0	62.0	4.90	II	2L
Pembrolizumab (200 mg every 3 wk)	vs Placebo	PD-1	NCT02702401	Advanced HCC	278	13.90	18.3	62.2	3.00	III	2L
Pembrolizumab (200 mg every 3 wk)	No	PD-1	NCT02658019	Advanced HCC	29	11.00	32.0	46.0	4.50	II	2L
Camrelizumab (200 mg every 2 wk)	vs Camrelizumab (200 mg q3w)	PD-1	NCT02989922	Advanced HCC	109	14.20	11.9	47.7	2.30	II	2L
Camrelizumab (200 mg every 3 wk)	vs Camrelizumab (200 mg q2w)	PD-1	NCT02989922	Advanced HCC	108	13.20	17.6	44.0	2.00	II	2L
Durvalumab (1500 mg every 4 wk)	vs T300+D and tremelimumab	PD-L1	NCT02519348	Unresectable HCC	104	13.60	10.6	37.5	2.07	II	Mix
Durvalumab (1500 mg every 4 wk)	vs T300+D and sorafenib	PD-L1	NCT03298451	Unresectable HCC	389	16.56	17.0	54.8	3.65	III	1L
Tremelimumab (750 mg every 4 wk)	vs T300+D and durvalumab	CTLA-4	NCT02519348	Unresectable HCC	69	15.10	7.2	49.3	2.69	II	Mix
Tislelizumab (5 mg/kg every 3 wk)	No	PD-1	NCT02407990	Advanced HCC	50		12.2	51.0		Ib	2L

1L: First-line therapy; 2L: Second-line therapy; CTLA-4: Cytotoxic T lymphocyte-associated antigen 4; DCR: Disease control rate; HCC: Hepatocellular carcinoma; mOS: Median overall survival; mPFS: Median progression free survival; NR: Not reached; ORR: Overall response rate; PD-1: Programmed cell death protein 1; PD-L1: Programmed death ligand 1; T300+D: Dose of tremelimumab (300 mg IV, cycle 1) combined with durvalumab (1500 mg IV once every 4 wk).